Embecta Corp

NASDAQ EMBC

Download Data

Embecta Corp Shares (Common, Diluted) 5 year CAGR for the year ending September 30, 2023

Embecta Corp Shares (Common, Diluted) 5 year CAGR is NA for the year ending September 30, 2023. Shares (Common, Diluted) represent the number of common shares outstanding, including potential dilution from stock options, convertible securities, or other instruments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Embecta Corp Shares (Common, Diluted) for the year ending September 30, 2022 was USD 57.06 M, a 0.44% change year over year.
  • Embecta Corp Shares (Common, Diluted) for the year ending September 30, 2021 was USD 56.80 M, a -0.34% change year over year.
  • Embecta Corp Shares (Common, Diluted) for the year ending September 30, 2020 was USD 57.00 M, a 0.00% change year over year.
  • Embecta Corp Shares (Common, Diluted) for the year ending September 30, 2019 was USD 57.00 M.
NASDAQ: EMBC

Embecta Corp

CEO Mr. Devdatt Kurdikar
IPO Date April 1, 2022
Location United States
Headquarters 300 Kimball Drive, Parsippany, NJ, United States, 07054
Employees 2,200
Sector Healthcare
Industry Medical instruments & supplies
Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

Similar companies

ANGO

AngioDynamics Inc

NA

NA

AKYA

Akoya Biosciences Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email